Organic Active Ingredients TRIZ Cases

Separating R-ketamine from S-ketamine targets inflammation and bone disease while addressing side effects that limit long-term treatment.

Limited camptothecin ADC options are addressed with fluoroalkyl payloads, defined DAR values, and targeted antibody delivery.

A split intra- and extragranular formulation packs raltegravir potassium into one tablet while preserving physical properties.

Formula (I) tetrahydronaphthalene compounds address limited survival in ER+, HER2- metastatic breast cancer through estrogen receptor degradation.

Repeated catheterization and slow drug response complicate AUR care; a single teverelix dose targets prostate enlargement to limit recurrence.

Oxycycloalkyl groups and modular linkers tune camptothecin ADC payloads for tumor targeting, antitumor activity, and toxicity profiles.

Specific 2′-halogen substitutions support efficient mRNA capping, in vitro transcription, cellular translation, and lower immunogenicity.

High-humidity exposure can increase related substances in FTD–TPI formulations; 85% critical-RH excipients help preserve stability.

A water-insoluble carrier lets saliva mobilize cannabinoids gradually, replacing rapid smoking absorption with adjustable oral dosing.

Specific amino acids promote caspase 14, desmoglein-1, and protein-glutamine γ-glutamyltransferase E production to improve moisture, barrier function, spots, and pH.

Acidified lower alcohol extraction, pH adjustment, and low-temperature crystallization produce cytisine at 98–99.9% purity and 80–85% yield.

A borate-polyol system with reduced benzalkonium chloride supports antimicrobial protection and ocular tolerability in multidose glaucoma treatment.

Oxidation-sensitive biopterin derivatives are stabilized in a solid phosphate-salt composition, then reconstituted for intravenous infusion.

Modified isoquinolinone derivatives use targeted substituents to improve membrane permeability and pharmacokinetics for glaucoma and ocular hypertension treatment.

RIAA selectively activates RIG-I to raise perforin and granzyme B in cytotoxic cells without unwanted interferon responses.

An ab-interno curved cannula reaches Schlemm’s canal through the anterior chamber, reducing external dissection and supporting aqueous humor drainage.

Phosphorothioate CpG oligonucleotides activate TLR9, raise interferon-gamma, and support durable tumor inhibition.

Immortalized corneal stromal stem cells produce defined exosome cargos for injection or contact-lens delivery to reduce and prevent scars.

A controlled oral release profile delivers 50% to 98% of daily minoxidil within 12 hours, limiting peak-related adverse effects.

A multi-ceramide topical composition boosts mitochondrial ATP production and respiratory-chain proteins to address oxidative damage and skin aging.

XRPD, DSC, and TGA distinguish crystalline and amorphous Bcl-2 inhibitor forms, supporting choices for solubility, stability, and bioavailability.

Target MYCT1 in endothelial cells to suppress tumor angiogenesis, enhance high endothelial venule formation, and create an immunostimulatory microenvironment.

Measure NRF2 splice variants and target genes to identify pathway-dependent cancers and guide antagonist treatment.

Hydroxyalkyl and heteroaryl substituents tune these compounds for NaV1.8 selectivity and potency while limiting off-target sodium channel effects.

To address cisplatin resistance in HGSOC, siRNA liposomes silence CASC10 and related targets to reduce tumor growth.

Conventional NASH therapies offer limited fibrosis and inflammation relief; CCK receptor inhibition targets the pathway to prevent HCC.

Topical corticosteroids and calcineurin inhibitors may provide incomplete relief; IL-4R antibody treatment lowers AD symptoms and biomarkers.

An ammonium sulfate inner phase and tuned lipid ratios help retain encapsulated drug, raise AUC, and limit insoluble particulates.

Combining an SGLT-2 inhibitor with an angiotensin II receptor blocker targets NAFLD fat accumulation in one treatment regimen.

Shortened and chemically modified hepcidin mimetics target ferroportin to reduce hematocrit in PV while easing synthesis.

Arginine solubilizes ibuprofen while the buffer-free injectable composition maintains near-physiological pH without sodium or dextrose.

Combining parathyroid hormone, osteoclast inhibitors, and a collagen-hydroxyapatite scaffold targets delayed healing while supporting bone formation.

An in situ HCl process in 1-propanol addresses costly, inefficient synthesis of diazaspiro pyridopyrimidinone pharmaceutical compounds.

MTAP loss elevates MTA in tumor cells; these tricyclic carboxamides target MTA-bound PRMT5 for greater selectivity over normal tissues.

HLA-matched peptides and TCR-bearing T cells target KK-LC-1 cancers, improving CTL induction and cytotoxic activity across HLA-C*14 and HLA-B*15.

GLP-2 derivatives target GVHD, including steroid-refractory cases, to improve survival and reduce disease symptoms.

This case shows how a 5′-O-acetoacetyl diacetyluridine prodrug improves oral uridine absorption while delivering acetoacetate for conversion to beta-hydroxybutyrate.

Plant-derived carotenoids may not increase butyrate production; microbial carotenoids shift gut composition and help restore intestinal barrier integrity.

Separate Telmisartan and SGLT-2 dosing can reduce convenience and compliance; a single tablet uses excipients to preserve stability and dissolution.

Protein hydrolysate-prebiotic conjugates resist digestive degradation while supporting sustained probiotic growth in the colon.

Limited antiviral efficacy and safety data motivate avermectin derivatives with tailored substituents for activity against SARS-CoV-2 and other coronaviruses.

Oral oxo-pyridine compounds target FXI to combine antithrombotic activity with rapid elimination and lower bleeding risk.

Forming a self-emulsifying delivery system before buffer addition stabilizes flavor emulsions and controls particle size in oral products.

A localized C4′ modification of the cannabidiol core creates a synthetic derivative with anticonvulsant activity in mouse models.

Targeted spermine-backbone modifications create SD1 to suppress type I interferon and interleukin-2 responses.

A localized Michael acceptor covalently binds KRAS G12C, inhibiting its pro-survival conformation with selective antiproliferative effects.

A medicated polymer sheath around a drug-loaded core supports independent, zero-order release of two active ingredients without dose dumping.

Low water solubility limits vitamin E glycosides in skin formulations; 1,2-hexanediol helps create a stable aqueous composition.

Acidic water with methanol or acetonitrile enables simple, accurate HPLC measurement of phenylhydrazine in pyrazolinone bulk drug.

Multiple crystal forms and X-ray diffraction profiles support stable KRAS G12D inhibitor development and storage.

This case uses casuarinin or stachyurin to activate muscle satellite cells and address age-related muscle loss with fewer side effects.

This case develops a shared heterocyclic scaffold for selective PAD4 inhibition, reducing citrullination and NET formation.

This case combines excipients and direct compression without milling to improve homogeneity, stability, and dissolution.

This case uses purified Antarctic brown algae β-glucan to improve solubility, support blood-cell recovery, and enhance antitumor therapy.

This case uses pidolate and malate acid salts to balance benzimidazole solubility, stability, and precipitation resistance in injections.

Receptor-mediated uptake delivers exon-skipping oligonucleotides to muscle cells, supporting functional dystrophin expression.

Modular FXR agonist design improves receptor activation while supporting treatment of cholestatic, metabolic, and liver disorders.

A surfactant-driven microemulsion encapsulates RAPA, raising solubility to 60 mg/mL while improving injection stability.

This case combines seviteronel, radiation, and optional dexamethasone to treat brain tumors through selective metalloenzyme inhibition.

This case uses sublingual mucosal absorption of tofacitinib to bypass gastrointestinal loss and improve treatment compliance.

An inactive membrane segment separates drug cores, reducing initial burst and supporting consistent release across storage conditions.

This case uses baseline and treatment-stage protein concentrations to predict JAK inhibitor response in GvHD subjects.

This case combines modified polynucleic acids, binding moieties, and polymers to improve delivery while limiting immune stimulation.

Controlled-release transdermal patches use treprostinil derivatives to improve systemic availability while avoiding injection trauma.

Hydrophobic carboxylate salts address polyamine absorption limits while supporting sustained plasma exposure without injections.

Crystalline diaminopyrimidine forms address poor solubility, stability, and dissolution.

Modified oxazolidinones target tuberculosis while limiting myelosuppression.

A capsule-triggered film unfolds on esophageal mucosa to extend residence time and improve local reflux inhibitor availability.

Quinazoline compounds selectively inhibit Kv1.5, Kv1.3, and Kv1.1 to prolong atrial refractoriness while limiting long QT risk.

This case uses a BRAF V600E animal model to support ganglioglioma diagnosis and inhibitor-based treatment of deep-tumor epilepsy.

Pyrazolylacetamides address ezogabine's side effects through selective Kv7.2/7.3 activation without affecting GABAA receptors.

This case tunes chiral ligands, metal precursors, and reaction conditions to produce C25 aminosterols with high diastereomeric excess.

An aqueous ethanol and TPGS formulation delivers ultra-low Resiniferatoxin doses for improved knee distribution and months-long pain relief.

Genetic testing matches ATR inhibitors to loss-of-function mutations, exploiting cancer cells’ reliance on ATR for DNA repair.

mRNA encodes multiple HCMV antigens to produce earlier, larger antibody responses across diverse patient groups.

This case uses viloxazine’s noradrenergic and receptor activities to treat ADHD with lower doses and an improved adverse-effect profile.

This case replaces thioether tethering with alkylamino links to form looped MT1-MMP ligands with better solubility and oxidation stability.

pH-responsive biodegradable components target intestinal release, improving local drug engagement while reducing systemic toxicity.

This case combines an anti-GREM1 antagonist with Ras-Raf-MEK-ERK inhibition to slow pancreatic tumor growth and extend response.

This case combines zongertinib with antibodies or ADCs to deepen tumor regression and address resistance in HER2-dependent cancers.

Reduced-dose cyclophosphamide supports marrow engraftment with resistant modified cells, limiting myeloablation, immune suppression, and infection risk.

This case uses fused heterocyclic compounds to target SOS1, interrupt KRAS activation, and inhibit RAS-driven cancer signaling.

Tumor cells are exposed to multilayer nanoparticles, then cytokines are measured to identify likely checkpoint-inhibitor responders.

This case uses 180–240 mg/day oral fasudil, a Rho kinase inhibitor, to slow sporadic ALS progression.

A fast-then-extended release profile helps maintain desglymidodrine levels for 8-12 hours while reducing dosing frequency.

This case shows how solvent, cooling, and pH control produce crystalline Form I for stable pharmaceutical processing.

This case uses rAAV-delivered inhibitory RNAs to reduce pathogenic DNM1 expression and address disease progression.

This case uses an oral naturally derived compound to activate AMPK, promote PGC-1α and GLUT4 expression, and support muscle maintenance.

This case uses citrate buffer and pH above 4.5 to keep metoclopramide nasal solutions clear and colorless during storage.

Defined X-ray diffraction patterns distinguish stable crystal forms, helping preserve SOS1-KRAS inhibitory activity in treatment.

Localized calcitriol creams, ointments, or patches relieve neuropathic pain while reducing excessive keratinocyte proliferation.

This case sequences chiral resolution, reduction, and nitrosation to produce high-purity Lumateperone tosylate intermediates.

This case uses naphthyridine derivatives to enhance M4 activity through an allosteric site while limiting peripheral side effects.

A PEG36-vitamin D scaffold prolongs PTH activity and improves calcium and phosphate outcomes while avoiding vitamin D receptor activity.

A hydrophilic outer layer, hydrophobic drug particles, and cationic agent support catheter integrity and targeted transfer.

Pectin microcapsules sustain vitamin C and nitrate release for radiotherapy salivary damage.

This case uses galectin-3 as a melanoma metastasis biomarker and therapeutic target, including ICI-resistant disease.

NMP, Vitamin E TPGS, and polymers keep SN-38 dissolved without precipitation for oral delivery and sustained release.

This case addresses microdamage from anti-resorptive drugs using delphinidin-rich maqui berry extract to stimulate bone repair.

Iron oxide-loaded polymer nanocapsules improve hydrophobic drug encapsulation and enable magnetic targeting with controlled release.

Pharmaceutical compositions hold at least 80 percent active ingredient by dry weight using specific excipients.

Adjusting cation exchange resin particles to 90-300 microns resolves the trade-off between nicotine stability and release rate in oral dosage forms.

Opioid compounds scavenge reactive oxygen species to suppress inflammatory responses and tumor metastasis in phototherapy.

Trametinib inhibits Erk1/2 activation to block mesothelial-to-mesenchymal transition, preventing abdominal adhesion and pulmonary fibrosis formation.

Pyrazole carboxamides selectively inhibit JAK1 to treat autoimmune diseases without causing anemia or thrombocytopenia from non-selective JAK2 inhibition.

Splicing inhibitors restore MHC class I expression on cancer cells, resolving immune evasion and enhancing tumor recognition.

HOP alkali metal salt cocrystals resolve poor water solubility and stability issues in pharmaceutical applications.

Merges BRAF inhibition with checkpoint blockade to boost CD8+ T-cell infiltration, addressing recurrence risks from single-agent therapies.

Anti-C5 antibodies target the C5 beta chain with pH-dependent binding to reduce hemolysis and tissue damage in paroxysmal nocturnal hemoglobinuria.

Formula I compounds activate PPARδ to treat metabolic disorders while improving in vivo stability.

Segmented coatings deliver immediate vasodilation followed by delayed diuresis to reduce peripheral edema while maintaining stable blood pressure control.

A water-soluble mannose oligosaccharide composition produced through microreactor polycondensation.

Compacting surface-reacted calcium carbonate without binders eliminates dust generation and simplifies dosage form production.

5-Aminolevulinic acid accumulates in cancer cells to generate protoporphyrin IX, enhancing anticancer effects at lower heating temperatures.

Terminal modifications with bridged nucleic acids reduce hepatotoxicity while preserving nuclease resistance and target mRNA binding.

Enzymatic hydrolysis of yeast cell wall beta-glucans improves bioavailability while preserving immune system stimulation properties.

Integrates mTOR inhibition with HER2 targeting to overcome limited survival outcomes in metastatic breast cancer treatment.

Spray drying converts polyunsaturated omega-3 fatty acids into oxidation-resistant lysine salts, eliminating rancidity without external antioxidants.

Sulfobutyl ether beta-cyclodextrin forms an inclusion complex with meloxicam to enhance aqueous solubility and bioavailability.

Plant-derived exosomes modulate cytokine production through microRNA delivery, addressing septic shock and organ failure risks.

Asymmetric cationic lipids encapsulate nucleic acids into stable nanoparticles, preventing degradation in aqueous environments.

Modified antibody-albumin nanoparticle complexes eliminate linker instability and reduce toxicity to healthy tissues while delivering paclitaxel to tumor cells.

Pyridazine-3-carboxamide derivatives target the TYK2 pseudokinase domain to resolve selectivity issues common with ATP-site inhibitors.

Solubilizing agents enable oral 17-hydroxyprogesterone ester delivery, replacing painful intramuscular injections.

Novel imidazole-thione compounds inhibit dopamine-beta-hydroxylase with peripheral selectivity.

Segmented powder packets deliver a stable, supersaturated calcium phosphate solution that relieves chronic xerostomia and mucositis discomfort.

Natural liquid composition coats esophageal mucosa with Aloe vera, hyaluronic acid, and honey to prevent reflux damage without pharmaceutical side effects.

A nutraceutical composition merges C60 fullerene with a COX-2 inhibitor to deliver combined antioxidant and anti-inflammatory effects.

Precipitating the sulfonyl chloride as an acid salt eliminates unstable diazonium intermediates, resolving purity versus recovery rate trade-offs.

Nox4 inhibitors block reactive oxygen species to prevent bone loss without disrupting osteoblast-mediated bone architecture.

Modified guide RNAs incorporate non-nucleic acid internal linkers to replace non-essential contacts.

Aqueous S-ketamine hydrochloride nasal spray formulation utilizes the drug's inherent antimicrobial properties to maintain stability without external preservatives.

Spray granulation merges drying and granulation into one fluidized bed step, eliminating costly downstream operations for industrial tableting.

Small molecule mimetics bind the p75 NTR receptor to promote neural cell survival, bypassing stability and bioavailability limits of full neurotrophins.

Single injectable progesterone implant releases hormone to permanently inhibit uterine gland development in female animals.

Lewis acid catalysis synthesizes dihydroartemisinin-steroid conjugates with potent tumor inhibition and low toxicity for non-small cell lung cancer treatment.

Poloxamer hydrogels stabilize DNAzymes via sol-gel transitions, preventing leakage during rectal administration.

Segmented RNAi constructs silence PNPLA3 to treat nonalcoholic fatty liver disease.

Segmented polyamine and ascorbic acid matrices maintain ingredient stability while stimulating wound healing and reducing aging signs.

Formula I compounds block the PRRSV-CD163 entry mechanism, overcoming vaccine limitations from high genetic heterogeneity.

Saccharide surfactant films encapsulate ibuprofen within nanoparticle carriers, preventing crystallization and improving bioavailability.

Pantothenate kinase inhibitors overcome antifungal drug resistance while activators address pantothenate kinase deficiency in neurodegenerative diseases.

Modified polynucleic acid molecules reduce PCSK9 expression and LDL levels while minimizing cytotoxicity through specific structural changes.

Bisphosphonate-oxazolidinone conjugates selectively deliver antibiotics to bone tissue via targeted binding mechanisms.

A UCP1 gene therapy vector expresses uncoupling protein 1 to reduce body fat mass and improve glucose tolerance.